Patents by Inventor Christiane Yoakim
Christiane Yoakim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7119099Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A,; X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.Type: GrantFiled: February 4, 2004Date of Patent: October 10, 2006Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Patent number: 7105510Abstract: Compounds represented by formula I: wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or (C1-4)alkyl; R3 is H or (C1-4)alkyl; R4 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cycloalkyl, or (C3-7)cycloalkyl; and Q is a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said Q being optionally substituted with hydroxy, or (C1-4)alkyl which in turn maybe optionally substituted with pyridinyl-N-oxide or C(O)OR wherein R is H or (C1-4)alkyl; or a salt thereof. The compounds have inhibitory activity against Wild Type, and single and double mutants strains, of HIV.Type: GrantFiled: September 15, 2003Date of Patent: September 12, 2006Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, Eric Malenfant, Bounkham Thavonekham, William Ogilvie, Robert Déziel
-
Publication number: 20060069261Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table.Type: ApplicationFiled: September 29, 2005Publication date: March 30, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Pierre Bonneau, Patrick Deroy, Alexandre Gagnon, Jeffrey O'Meara, Bruno Simoneau, Christiane Yoakim
-
Publication number: 20060025480Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: July 19, 2005Publication date: February 2, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Jeffrey O'Meara, Christiane Yoakim
-
Publication number: 20050282907Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: May 24, 2005Publication date: December 22, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Patrick Deroy, Anne-Marie Faucher, Alexandre Gagnon, Serge Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20050054639Abstract: Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.Type: ApplicationFiled: November 21, 2003Publication date: March 10, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Anne-Marie Faucher, Serge Landry, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20050009855Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A,; X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.Type: ApplicationFiled: February 4, 2004Publication date: January 13, 2005Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, Bruno Hache, William Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Patent number: 6825176Abstract: The present invention generally relates to an assay for identifying inhibitors of Human Papillomavirus (HPV), comprising: a) contacting a HPV E2 transactivation domain with a probe to form a E2:probe complex and measuring a signal from said probe to establish a base line level; b) incubating the E2:probe complex with a test compound and measuring the signal from said probe; c) comparing the signal from step b) with the signal from step a); wherein said probe is a compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein R1, A, X, W, Y, R3 and R4 are as defined herein; or a derivative thereof, wherein said derivative is a probe of formula (I) labeled with a detectable label or an affinity tag, wherein wavy lines represent bonds of unspecified stereochemistry; and wherein said signal is selected from: fluorescence, resonance energy transfer, time resolved fluorescence, radioactivity, fluorescence polarization, change in the intrinsic spectral properties, luminescenceType: GrantFiled: February 5, 2003Date of Patent: November 30, 2004Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Peter White, Christiane Yoakim
-
Patent number: 6806265Abstract: Compounds represented by formula I: wherein R2 is selected from the group consisting of H, (C1-4)alkyl, halo, haloalkyl, OH, (C1-6)alkoxy, NH(C1-4alkyl) or N(C1-4alkyl)2; R4 is H or Me; R5 is H or Me; R11 is H, (C1-4)alkyl, (C3-4)cycloalkyl and (C1-4)alkyl-(C3-4)cycloalkyl; A is a connecting chain of (C1-3)alkyl; B is O or S; n is 0 or 1; wherein when n is 0: Ring C is 6- or 10-membered aryl or 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from the group consisting of O, N, and S, said aryl and said heterocycle being optionally substituted; and E is CONR12R13; CONHNR14R15; NR16COR17; NR18SO2(C1-6)alkyl; SO2NR19R20; or SO2R21; or when n is 1: Ring C is as defined above and E is a single bond or a connecting group; and Ring D is 6- or 10-membered aryl or 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from the group consisting of O, N, and S, said aryl and said heterocycle being optionally substituted with from 1 to 5 substituents; or a salt orType: GrantFiled: May 6, 2003Date of Patent: October 19, 2004Assignee: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Serge Landry, Eric Malenfant, Julie Naud, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20040132723Abstract: Compounds represented by formula 1: 1Type: ApplicationFiled: September 15, 2003Publication date: July 8, 2004Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, Jeffrey O'Meara, Bruno Simoneau, William Ogilvie, Robert Deziel
-
Patent number: 6759409Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A,; X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.Type: GrantFiled: December 17, 2001Date of Patent: July 6, 2004Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, Bruno Haché, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Publication number: 20040106791Abstract: Compounds represented by formula I: 1Type: ApplicationFiled: September 15, 2003Publication date: June 3, 2004Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, Eric Malenfant, Bounkham Thavonekham, William Ogilvie, Robert Deziel
-
Patent number: 6706706Abstract: Disclosed are compounds of formula I: wherein R2 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, NH(C1-4alkyl) or N(C1-4alkyl)2; R4 is H or CH3; R5 is H or CH3; R12 is H, halogen, (C1-4)alkyl, CF3, or NO2; R13 is H, (C1-4)alkyl, halogen, OH, or NH2, with the proviso that R12 and R13 are not both H; and R14 is COOR14a wherein R14a is H or (C1-6)alkyl; or R14 is (C2-4)alkenyl-COOR14a wherein R14a is as defined herein; or R14 is (C1-4)alkyl-COOR14a wherein R14a is as defined above; or a salt or a prodrug thereof, useful as inhibitors of HIV reverse transcriptase.Type: GrantFiled: March 4, 2003Date of Patent: March 16, 2004Assignee: Boehringer Ingelheim International GmbHInventors: Jeffrey O'Meara, Bruno Simoneau, Christiane Yoakim, Robert Déziel, William W. Ogilvie
-
Publication number: 20040006071Abstract: Compounds represented by formula I: 1Type: ApplicationFiled: May 6, 2003Publication date: January 8, 2004Applicant: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Serge Landry, Eric Malenfant, Julie Naud, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20030194698Abstract: The present invention generally relates to an assay for identifying inhibitors of Human Papillomavirus (HPV), comprising:Type: ApplicationFiled: February 5, 2003Publication date: October 16, 2003Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Peter White, Christiane Yoakim
-
Publication number: 20030195197Abstract: Disclosed are compounds of formula I: 1Type: ApplicationFiled: March 4, 2003Publication date: October 16, 2003Applicant: Boehringer Ingelheim International GmbHInventors: Jeffrey O'Meara, Bruno Simoneau, Christiane Yoakim, Robert Deziel, William W. Ogilvie
-
Publication number: 20030082769Abstract: A crystallizable composition, comprising an PV E2 TAD-like polypeptide of SEQ ID NO.2 complexed with an inhibitor L. The invention also provides a method for producing the crystallized HPV E2 TAD-inhibitor complex (HPV E2 TAD-L) comprising: a) mixing purified HPV E2 TAD, contained in a purfication buffer, with solublized inhibitor L to generate a complex solution containing the HPV E2 TAD-L complex; and b) crystallizing the complex from a) in a crystallization buffer. The invention also provides a method for producing crystallized apo HPV E2 TAD, comprising: a) mixing apo HPV E2 TAD, contained in a purification buffer, with a crystallization buffer. X-ray crystal structure coordinates the HPV E2 TAD-L complex, are also provided, which define an inhibitor binding pocket. The inhibitor binding pocket is useful for screening potential small molecule inhibitors that bind to the pocket.Type: ApplicationFiled: July 11, 2002Publication date: May 1, 2003Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Dale R. Cameron, Jacques Archambault, Christiane Yoakim, Peter White, Yong Wang
-
Publication number: 20030064985Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: 1Type: ApplicationFiled: December 17, 2001Publication date: April 3, 2003Inventors: Christiane Yoakim, Bruno Hache, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Patent number: 6242439Abstract: A compound of formula I wherein R1 is hydrogen, methyl, ethyl, methoxy or methylthio; R2 and R3 each independently is hydrogen or lower alkyl; R4 is hydrogen, lower alkyl, methoxy, ethoxy or benzyloxy; R5 is lower alkyl, lower cycloalkyl, (CH2)mC(O)OR6 wherein m is the integer 1 or 2 and R6 is lower alkyl, phenyl optionally substituted; optionally Het or Het(lower alkyl); or R4 and R5 together with the nitrogen atom to which they are attached form a nitrogen containing ring optionally substituted with C(O)O-benzyl or with phenyl optionally substituted with C(O)OR7 wherein R7 is lower alkyl or (lower alkyl)phenyl; and Z is lower alkyl or optionally substituted phenyl or Het; with the proviso that when Z is (CH2)p-(Het), then R2 and R3 each is hydrogen; or a therapeutically acceptable acid addition salt thereof which compound is useful in the treatment of HCMV infections.Type: GrantFiled: October 6, 1998Date of Patent: June 5, 2001Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, Robert Déziel, Jeffrey O'Meara, William W. Ogilvie
-
Patent number: 6211170Abstract: A compound of formula I: wherein R1 is hydrogen, methyl, ethyl, methoxy or methylthio; R2 and R3 each independently is hydrogen or C1-3 alkyl; R4 is hydrogen, lower alkyl, methoxy, ethoxy, or benzyloxy; R5 is lower alkyl, lower cycloalkyl, (CH2)mC(O)OR6 wherein m is the integer 1 or 2 and R6 is lower alkyl, phenyl optionally substituted with C(O)OR7 wherein R7 is lower alkyl or phenyl (lower alkyl); or R6 is Het or Het(lower alkyl; or R4 and R5 together with the nitrogen atom to which they are attached form a nitrogen containing ring optionally substituted with benzyloxycarbonyl or with phenyl optionally substituted among other group with C(O)OR7 wherein R7 is lower alkyl or (lower alkyl)phenyl; X is selected from the group consisting of O, S, SO, SO2, NR8, wherein R8 is H or lower alkyl; and Y is C1-10 non-cyclic or cyclic alkyl; [(CH2)0-1]-phenyl, said phenyl ring optionally substituted; Het or Het(lower alkyl); or when X is NR8, wherein R8 is lower alkyl and Y is lower alkyl orType: GrantFiled: October 6, 1998Date of Patent: April 3, 2001Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, Robert Déziel, Stephen Kawai, William W. Ogilvie, Jeffrey O'Meara, Catherine Chabot